Result of Annual General Meeting

e-Therapeutics plc

18 July 2023

 

e-therapeutics plc

("e-therapeutics" or the "Company")

Result of Annual General Meeting

London, UK, 18 July 2023 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a company integrating computational power and biological data to discover life-transforming RNAi medicines, announces that at its Annual General Meeting held earlier today, all resolutions, as set out in the Notice of Meeting, were duly passed.

The votes were as follows:

Resolution	Votes For	%	Votes Against	%	Abstentions	Resolution Result
Ordinary Resolution 1	370,258,508	100	0	0	0	Passed
Ordinary Resolution 2	370,250,879	99.9	3,463	0.001	4,166	Passed
Ordinary Resolution 3	370,250,879	99.9	3,463	0.001	4,166	Passed
Ordinary Resolution 4	370,255,045	99.9	3,463	0.001	0	Passed
Ordinary Resolution 5	370,196,546	99.9	38,462	0.010	23,500	Passed
Special Resolution 6	370,195,129	99.9	39,879	0.011	23,500	Passed

Enquiries:

e-therapeutics plc
Ali Mortazavi, CEO Timothy Bretherton, Director of Finance and Operations	Tel: [phone] www.etherapeutics.co.uk
SP Angel Corporate Finance LLP	Tel: [phone]
Nominated Adviser and Broker
Matthew Johnson/Harry Davies-Ball (Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)

About e-therapeutics plc

e-therapeutics plc ("ETX") integrates computational power and biology information to discover life-transforming RNAi medicines.  The Company's technology uses computation to capture and model human biology, identify novel targets, and develop RNAi medicines against those targets that can be rapidly progressed to the clinic. 

ETX's proprietary HepNetTM platform enables the generation and analysis of biological network models, providing a novel and mechanistic approach to drug discovery. This approach explicitly considers the true complexity of biology to make more reliable predictions from large complex data sets and ETX's proprietary hepatocyte knowledgebase - the world's most comprehensive and integrated hepatocyte-centric data resource.  The Company generates, prioritises and tests millions of hypotheses in silico to identify better therapeutic targets with higher confidence. 

GalOmicTM, ETX's proprietary RNAi platform, enables the targeted delivery to hepatocytes in the liver and the specific silencing of novel disease-associated genes, identified by HepNetTM.  The focus on hepatocytes offers the opportunity to tackle a wide variety of diseases.  The liver is a highly metabolically active organ which performs a key role in many biological processes and vital functions crucial for human health. ETX's GalOmicTM constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action.

The Company is progressing a pipeline of first-in-class preclinical RNAi candidates across several high unmet medical needs in cardiometabolic indications and targeting promising hepatocyte-expressed targets with effects in other disease areas. ETX has also partnered with biopharma companies such as Novo Nordisk, Galapagos NV and iTeos Therapeutics using its computational network biology approach across a diverse range of drug discovery projects.

The Company is based in London, UK and listed on the Alternative Investment Market of the London Stock Exchange ("AIM"), with ticker symbol ETX. E-therapeutics is also traded on the OTCQX Best Market (OTCQX) in the United States, under ticker symbol ETXPF.

 

END